Enanta Pharmaceuticals | ENTA - Ordinary Share Capital


Enanta Pharmaceuticals reported $212K in Ordinary Share Capital for its fiscal quarter ending in December of 2023.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Amgen USD 540M 1000K Mar/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 137.39M 1.69M Dec/2025
AstraZeneca USD 1.55B 73K Mar/2026
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Gilead Sciences USD 1.24B 1000K Mar/2026
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Immunic USD 120.38M 21.73M Dec/2025
Incyte USD 199.95M 1.49M Mar/2026
Insmed USD 216.52M 2.27M Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
J&J USD 2.41B 1.35M Mar/2026
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Merck USD 2.47B 12.72M Dec/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Novartis USD 1.91B 60K Mar/2026
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 13M Mar/2026
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Roche Holding CHF 796.77M 1.15M Jun/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026